Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.

Bale TA, Sait SF, Benhamida J, Ptashkin R, Haque S, Villafania L, et al. Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY). Acta Neuropathol. 2021;141(1):123-125.

Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, et al. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. J Rheumatol. 2021;48(4):541-547.

Ke Q, Dinalankara W, Younes L, Geman D, Marchionni L. Efficient representations of tumor diversity with paired DNA-RNA aberrations. PLoS Comput Biol. 2021;17(6):e1008944.

Baquero J, Tang X-, Scognamiglio T, Gudas LJ. EZH2 Knockout in Oral Cavity Basal Epithelia Causes More Invasive Squamous Cell Carcinomas. Carcinogenesis. 2021.

Mostyka M, Fulmer CG, Hissong EM, Yantiss RK. Crohn Disease Infrequently Affects the Appendix and Rarely Causes Granulomatous Appendicitis. Am J Surg Pathol. 2021.

Hansen G, Marino J, Wang Z-, Beavis KG, Rodrigo J, Labog K, et al. Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. J Clin Microbiol. 2021;59(2).

Wangsiricharoen S, Wakely PE, Siddiqui MT, Ali SZ. Cytopathology of chondromyxoid fibroma: a case series and review of the literature. J Am Soc Cytopathol. 2021;10(4):366-381.

Yantiss RK, Qin L, He B, Crawford CV, Seshan S, Patel S, et al. Intestinal Abnormalities in Patients With SARS-CoV-2 Infection: Histopathologic Changes Reflect Mechanisms of Disease. Am J Surg Pathol. 2021.

Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham C-, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. Antimicrob Agents Chemother. 2021;65(11):e0120421.